Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 9/20 | 0.50 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056165 | 1.00 | FBP1 (0.50) | FBP1PTP4A3HSP90AA1ALDH1A1MAPT | |
| SCHEMBL28627476 | 0.89 | FBP1 (0.49) | FBP1HSP90AA1ALDH1A1MAPTALOX12 | |
| SCHEMBL28627478 | 0.89 | FBP1 (0.49) | FBP1HSP90AA1ALDH1A1MAPTALOX12 | |
| SCHEMBL1010124 | 0.78 | NFKB1 (0.54) | FBP1ALDH1A1RXRAMAOAMAOB | |
| SCHEMBL1010123 | 0.78 | NFKB1 (0.54) | FBP1ALDH1A1RXRAMAOAMAOB | |
| SCHEMBL18524114 | 0.77 | FBP1 (0.53) | FBP1HSP90AA1ALDH1A1MAPTALOX12 | |
| SCHEMBL20177880 | 0.77 | FBP1 (0.53) | FBP1HSP90AA1ALDH1A1MAPTALOX12 | |
| SCHEMBL28513339 | 0.77 | ERN1 (0.55) | FBP1HSP90AA1ALDH1A1MAPTALOX12 | |
| SCHEMBL18524115 | 0.77 | FBP1 (0.53) | FBP1HSP90AA1ALDH1A1MAPTALOX12 | |
| SCHEMBL30259520 | 0.77 | FBP1 (0.53) | FBP1HSP90AA1ALDH1A1MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| EP-2794563-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093842-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | FBP1 3335/4885PTP4A3 3770/4885HSP90AA1 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.